Close Menu

NEW YORK (GenomeWeb) – Natera said today that it will join the Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and Molecular Analysis 2 (I-SPY 2) clinical trial, a multi-center study evaluating the combination of investigational therapies and neoadjuvant treatment in women with breast cancer.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.